About 460,000 results
Open links in new tab
  1. Eovist is a contrast agent that has magnetic properties. It is used in combination with magnetic resonance imaging (MRI) to allow blood vessels, organs, and other non-bony tissues to be seen more clearly.
    • Eovist is a prescription medicine called a gadolinium-based contrast agent (GBCA). Eovist, like other GBCAs, is injected into your vein and used with a magnetic resonance imaging (MRI) scanner. • An MRI exam with a GBCA, including Eovist, helps your doctor to see problems better than an MRI exam without a GBCA.
    www.emersonhospital.org/EmersonHospital/media/…
    Eovist (gadoxetate disodium) is a contrast agent that produces magnetic effects and is used in combination with magnetic resonance imaging (MRI) to help diagnose certain disorders of the liver.
  2. People also ask
  3. Eovist-injection | Radiology Global Master V1

  4. Eovist - Questions and Answers in MRI

    Eovist is a gadolinium-based contrast agent that accumulates in hepatocytes and is excreted into the biliary tract. It is used for liver imaging to assess vascularity and function of liver lesions. Learn how it works, when to use it, and what are …

  5. Hyperintense Liver Masses at Hepatobiliary Phase …

    Dec 13, 2019 · Gadoxetic acid (gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid [Eovist or Primovist; Bayer Healthcare, Berlin,Germany]) is a …

    • Author: Nobuhiro Fujita, Akihiro Nishie, Yoshiki Asayama, Kousei Ishigami, Yasuhiro Ushijima, Daisuke Kakiha...
    • Publish Year: 2020
  6. Hepatocellular carcinoma | Radiology Reference Article

  7. Gadoxetate Disodium–Enhanced MRI of the Liver: Part …

    Nov 23, 2012 · Currently, two contrast agents, gadoxetate disodium (Gd-EOB-DTPA, gadoxetic acid, Eovist or Primovist, Bayer HealthCare) and gadobenate dimeglumine (MultiHance, Bracco), are commercially available in the United …

  8. [PDF]

    EOVIST

  9. Eovist Injection and Resovist Injection: Two New Liver-Specific ...

  10. Focal nodular hyperplasia | Radiology Reference Article

  11. Some results have been removed